Designing a Phase 1 Single-Ascending-Dose Study of a Subcutaneous TACI-Fc Fusion Protein in Healthy Adults: Starting-Dose Derivation, Safety Gating, and Protocol Synopsis
A biologic that suppresses immunoglobulins and B cells for months asks a healthy volunteer to carry a risk with no personal benefit, so every element of a first-in-human design must be justified against that fact. This article develops a hypothetical Phase 1 single-ascending-dose study of a subcutaneous TACI-Fc fusion protein that neutralizes the cytokines BAFF and APRIL, intended for later development in a B-cell-driven kidney disease. It derives a 2 mg starting dose from assumed toxicology and pharmacologically active dose benchmarks, sets six planned dose cohorts and one optional cohort from 2 to 600 mg, and gates each escalation by sentinel dosing, a Safety Review Committee, an exposure cap, and immunoglobulin-based stopping rules. The synopsis specifies 48 randomized participants (up to 56), a 113-day follow-up with extension for persistent suppression, a pharmacokinetic and pharmacodynamic sampling plan, and a descriptive statistical analysis that includes a dose-proportionality criterion. Every nonclinical value is an explicit planning assumption, and the arithmetic is shown so that real data can replace it.Keywords: first-in-human; fusion protein; BAFF; APRIL; healthy volunteers; ICH S6(R1); sentinel dosing; minimal anticipated biological effect level
Authors
- Peivand Pirouzi
- Perpetua Ulofu
- Uchechukwu Veronica Ikechukwu
- Yemurayi Hungwe
- Precious Chinenye Sunday
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426235
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00